scholarly journals No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir

2017 ◽  
Vol 73 (1) ◽  
pp. 173-176 ◽  
Author(s):  
Marine Perrier ◽  
Benoit Visseaux ◽  
Roland Landman ◽  
Véronique Joly ◽  
Eve Todesco ◽  
...  
Keyword(s):  
Virological Response ◽  
First Line ◽  
Hiv 1

Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients

AIDS ◽  
2002 ◽  
Vol 16 (14) ◽  
pp. 1867-1876 ◽  
Author(s):  
Andrea Antinori ◽  
Maria Letizia Giancola ◽  
Susanna Grisetti ◽  
Fabio Soldani ◽  
Lucia Alba ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Virological Response ◽  
Antiretroviral Drugs ◽  
Factors Influencing ◽  
Hiv 1

scholarly journals Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy

AIDS ◽  
2013 ◽  
Vol 27 (4) ◽  
pp. 553-561 ◽  
Author(s):  
Mary-Ann A. Etiebet ◽  
James Shepherd ◽  
Rebecca G. Nowak ◽  
Man Charurat ◽  
Harry Chang ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
First Line ◽  
Hiv 1

Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen

2018 ◽  
Vol 74 (3) ◽  
pp. 718-721
Author(s):  
Chloé Dimeglio ◽  
Stéphanie Raymond ◽  
Florence Nicot ◽  
Nicolas Jeanne ◽  
Romain Carcenac ◽  
...  
Keyword(s):  
Virological Response ◽  
Mutational Load ◽  
First Line

scholarly journals Drug Resistance-Associated Mutations in Antiretroviral Treatment-Experienced Patients in Kuwait

2018 ◽  
Vol 27 (2) ◽  
pp. 152-157
Author(s):  
Wassim Chehadeh ◽  
Osama Albaksami ◽  
Sonia Elezebeth John ◽  
Widad Al-Nakib
Keyword(s):  
Reverse Transcriptase ◽  
Transcriptase Inhibitor ◽  
Antiretroviral Drugs ◽  
First Line ◽  
Genotypic Resistance ◽  
Nonnucleoside Reverse Transcriptase Inhibitor ◽  
High Level ◽  
Interpretation Algorithm ◽  
Hiv 1 ◽  
Level Resistance

Objectives: To investigate the prevalence of nonpolymorphic resistance-associated mutations (RAM) in HIV-1 patients on first-line antiretroviral therapy in Kuwait. Subjects and Methods: Total RNA was isolated from plasma samples of 42 patients who received a first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen. HIV-1 protease and reverse transcriptase genetic regions were then amplified by nested reverse transcription-polymerase chain reaction and directly sequenced. The HIV-1 subtype was identified using the Bayesian phylogenetic method, and RAM were identified using the Stanford University genotypic resistance interpretation algorithm. Results: The HIV-1 viral load at sampling ranged from < 20 to 8.25 × 104 copies/ml. CRF01_AE, C, and B were the most predominant HIV-1 subtypes. Nonpolymorphic mutations associated with resistance to antiretroviral drugs were detected in 11 (26.2%) of the 42 patients; 5 (11.9%) patients had mutations associated with a high-level resistance to nucleoside reverse transcriptase inhibitors (NRTI), 4 (9.5%) patients had mutations associated with resistance to NNRTI, 1 (2.4%) patient had mutations associated with resistance to both NRTI and NNRTI, and 1 (2.4%) patient had mutations potentially associated with low-level resistance to both protease inhibitors and NNRTI. All patients with RAM had a detectable plasma HIV-1 RNA level. Conclusion: Our results indicate the development of RAM during an NNRTI-based regimen and highlight the importance of considering other regimens to avoid treatment failure.

Sign in / Sign up

Export Citation Format

Share Document